Natera Says Its Signatera Test Gets Japan Approval as Bladder Cancer Companion Diagnostic

08:41 AM EDT, 09/22/2026 (MT Newswires) -- Natera (NTRA) said Tuesday that Japan's Pharmaceuticals and Medical Devices Agency has approved the company's Signatera test as a companion diagnostic for muscle-invasive bladder cancer. The approval supports using Signatera to guide adjuvant atezolizumab treatment decisions in patients with muscle-invasive bladder cancer, the company said. Natera said it expects to commercially launch the test in Japan in H1 of next year, following approval of atezolizumab for the indication. The approval was supported by data from the late-stage IMvigor011 trial, the company said.